Acceleron Pharma (XLRN) PT Lowered to $68 at H.C. Wainwright

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Acceleron Pharma (XLRN) PT Lowered to $68 at H.C. Wainwright

Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Facioscapulohumeral Muscular Dystrophy

September 16, 2019 4:30 PM EDT

ACE-083 did not achieve statistically significant improvements in functional endpoints relative to placebo

Acceleron to discontinue development of ACE-083 in facioscapulohumeral muscular dystrophy

Topline results from the Phase 2 trial of ACE-083 in Charcot-Marie-Tooth disease expected in Q1 2020 -

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that treatment with ACE-083 in patients with facioscapulohumeral muscular dystrophy (FSHD) did not achieve functional... More